Vaccine makers rose after the first bird flu death was reported in the U.S.

Novavax up 14%, Moderna up 12%, CureVac up 11%, BioNTech up 5%, Pfizer up 2%.

Moderna is one of a few drugmakers currently developing a vaccine for the H5N1 bird flu, which is spreading rapidly through farms and wild animals in North America.

As of Jan. 6, there have been 66 confirmed human cases of H5N1 bird flu in the U.S. since 2024 and 67 since 2022, according to the Centers for Disease Control and Prevention.

Pfizer and GSK in partnership with CureVac are also developing mRNA vaccines for bird flu.

CureVac, a Germany-based biotech with a market cap of just under $1 billion, rose in Tuesday trading after a 23% gain Monday.